Seroresponse and postvaccination seroprotection in the cohort, n (%)
| . | A . | C . | W . | Y . | P value seroresponse rate difference (<1:8 - ≥1:8) across serogroup . |
|---|---|---|---|---|---|
| Seroresponse | 86/100 (86) | 78/100 (78) | 83/100 (83) | 68/100 (68) | 0.21 |
| <1:8 prevaccination | 68/73 (93) | 65/79 (82) | 59/70 (85) | 53/78 (69) | |
| ≥1:8 prevaccination | 18/27 (67) | 13/21 (62) | 24/30 (79) | 12/22 (64) | |
| Postvaccination seroprotection∗ | 97/101 (96) | 87/101 (86) | 89/101 (88) | 77/101 (76) | 0.45 |
| <1:8 prevaccination | 69/73 (95) | 65/79 (82) | 59/70 (85) | 54/78 (69) | |
| ≥1:8 prevaccination | 27/27 (100) | 21/21 (100) | 29/30 (97) | 22/22 (100) |
| . | A . | C . | W . | Y . | P value seroresponse rate difference (<1:8 - ≥1:8) across serogroup . |
|---|---|---|---|---|---|
| Seroresponse | 86/100 (86) | 78/100 (78) | 83/100 (83) | 68/100 (68) | 0.21 |
| <1:8 prevaccination | 68/73 (93) | 65/79 (82) | 59/70 (85) | 53/78 (69) | |
| ≥1:8 prevaccination | 18/27 (67) | 13/21 (62) | 24/30 (79) | 12/22 (64) | |
| Postvaccination seroprotection∗ | 97/101 (96) | 87/101 (86) | 89/101 (88) | 77/101 (76) | 0.45 |
| <1:8 prevaccination | 69/73 (95) | 65/79 (82) | 59/70 (85) | 54/78 (69) | |
| ≥1:8 prevaccination | 27/27 (100) | 21/21 (100) | 29/30 (97) | 22/22 (100) |
Prevaccination serostatus was not available for 1 participant.